Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genta Will Appeal FDA “Not Approvable” Action On Genasense

Feb 06 2007

• By Shirley Haley

Related Content

Genasense User Fee Date For CLL Extended Following New Data Submission

Oct 30 2006

Lilly To Appeal FDA Action On Arxxant Calling For Additional Clinical Trial

Oct 19 2006

Genta CLL Agent Genasense Has Not Shown Clinical Benefit, FDA Panel Says

Sep 06 2006

Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint

Dec 15 2006

Epix President Andrew Uprichard: An Interview With "The Pink Sheet" DAILY

Dec 15 2006

Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007

Nov 09 2006

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window